.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP11_Grazoprevir.Grazoprevir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP11_Grazoprevir.Grazoprevir| name: | Grazoprevir |
| ATC code: | J05AP11 | route: | oral |
| n-compartments | 2 |
Grazoprevir is an oral inhibitor of the hepatitis C virus (HCV) NS3/4A protease, approved for use in combination with elbasvir for the treatment of chronic HCV genotype 1 and 4 infections in adults. It is used as part of direct-acting antiviral regimens and is currently approved and used in clinical practice.
Pharmacokinetics in healthy adult subjects, oral administration of single 100 mg dose.
Landaverde, C, et al., & Goldstein, JL (2016). Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection. Expert review of gastroenterology & hepatology 10(4) 419–429. DOI:10.1586/17474124.2016.1147346 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26818134
Roth, D, et al., & Greaves, W (2015). Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet (London, England) 386(10003) 1537–1545. DOI:10.1016/S0140-6736(15)00349-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26456905
Marshall, WL, et al., & Yeh, WW (2018). Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. European journal of drug metabolism and pharmacokinetics 43(3) 321–329. DOI:10.1007/s13318-017-0451-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29247332